The short version of reversed-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-21. Anything still debated is marked as such rather than presented as settled.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilized peptide powder form |
| Solubility | Soluble in aqueous buffer | Dissolves in water and buffered saline |
| Typical storage temperature | 2 to 8 degrees Celsius | Refrigerated; protect from freezing and light |
| Common analytical method | Reversed-phase HPLC | Purity and related substances |
| Mass confirmation | Electrospray mass spectrometry | Verifies approximately 4,813 Da |
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
=== N05AB Phenothiazines with piperazine structure === N05AB01 Dixyrazine N05AB02 Fluphenazine N05AB03 Perphenazine N05AB04 Prochlorperazine N05AB05 Thiopropazate N05AB06 Trifluoperazine N05AB07 Acetophenazine N05AB08 Thioproperazine N05AB09 Butaperazine N05AB10 Perazine N05AB13 Metofenazate
MDDMA, or MDDM, also known as 3,4-methylenedioxy-N,N-dimethylamphetamine or as N,N-dimethyl-MDA or N-methyl-MDMA, is a psychoactive drug of the phenethylamine, amphetamine, and MDxx families. It is the N,N-dimethyl analogue of MDA and the N-methyl derivative of MDMA. The drug is a known synthetic impurity of MDMA and has also been described as a possible novel designer drug in 2025. In addition, (R)-MDDMA was characterized as a non-hallucinogenic psychoplastogen with antidepressant-like effects and improved safety relative to MDMA in 2026.
government terminates a deal with Eli Lilly and Company for 350,856 remaining doses of the single antibody bamlanivimab that were scheduled to be delivered by the end of March. The deal will instead be focused on a supply of combined antibodies with etesevimab. Microsoft announces the $20 billion acquisition of AI firm Nuance Communications, the second largest deal in its history, after LinkedIn in 2016. April 15 Chicago police release graphic footage of an officer shooting dead 13-year-old Adam Toledo in a dark alley. Indianapolis FedEx shooting: Nine people are killed, including the shooter, and seven injured, in a mass shooting at a FedEx facility in Indianapolis. April 16 The media reports that U.S. Republican Representatives Marjorie Taylor Greene and Paul Gosar are forming the America First Caucus. It is scrapped within a day, following criticism from other GOP members. COVID-19 drug development: The U.S. Food and Drug Administration (FDA) revokes the emergency use authorization (EUA) for bamlanivimab. COVID-19 pandemic Virginia reports its first two cases of the Lineage P.1 variant, which was originally detected in Brazil. Michigan extends their restrictions on gatherings and dining to May 24 amid a rise of cases. The state also expands their mask mandate to children ages 2–4 years. The number of vaccines administered in the United States exceeds 200 million. April 18 – COVID-19 vaccination: The CDC reports that over 50% of Americans have received at least one dose of a COVID-19 vaccine.
Sources: en.wikipedia.org
=== Dopamine === Dopamine is a neurotransmitter that regulates arousal, motivation, muscular coordination, and endurance performance, among other things. Dopamine levels have been found to be lower after prolonged exercise. A decrease in dopamine can decrease athletic performance as well as mental motivation. Dopamine itself cannot cross the blood brain barrier and must be synthesized within the brain. In rats bred for running, increased activity of the ventral tegmental area have been observed, and VTA activity correlates with voluntary wheel running. As the VTA is an area dense in dopaminergic neurons that project to many areas of the brain, this suggests that dopaminergic neurotransmission drives physical performance. Further supporting this theory is the fact that dopamine reuptake inhibitors as well as norepinephrine dopamine reuptake inhibitors are able to increase exercise performance, especially in the heat.
Of great importance to the model building effort of Watson and Crick was Rosalind Franklin's understanding of basic chemistry, which indicated that the hydrophilic phosphate-containing backbones of the nucleotide chains of DNA should be positioned so as to interact with water molecules on the outside of the molecule while the hydrophobic bases should be packed into the core. Franklin shared this chemical knowledge with Watson and Crick when she pointed out to them that their first model (from 1951, with the phosphates inside) was obviously wrong. Crick described what he saw as the failure of Wilkins and Franklin to cooperate and work towards finding a molecular model of DNA as a major reason why he and Watson eventually made a second attempt to do so. They asked for, and received, permission to do so from both William Lawrence Bragg and Wilkins. To construct their model of DNA, Watson and Crick made use of information from unpublished X-ray diffraction images of Franklin's (shown at meetings and freely shared by Wilkins), including preliminary accounts of Franklin's results/photographs of the X-ray images that were included in a written progress report for the King's College laboratory of Sir John Randall from late 1952. It is a matter of debate whether Watson and Crick should have had access to Franklin's results without her knowledge or permission, and before she had a chance to formally publish the results of her detailed analysis of her X-ray diffraction data which were included in the progress report.
Counter-Strike – A team-based tactical first-person shooter game involving rounds of combat between two teams, counter-terrorists and terrorists. Counter-Strike was later released commercially by Valve as a standalone game. Day of Defeat – A World War II first-person shooter, originally a mod and later a commercially released game. Deathmatch Classic – An official mod by Valve that updates the multiplayer gameplay from id Software's Quake, featuring enhanced textures, models, and lighting. It was released on June 7, 2001, and included in an update to Half-Life a month later. OS X and Linux ports of the Windows game were released through Steam in August 2013. Deathmatch Plus – A mod split off from Oz Deathmatch. The mod has a "Lights Out" mode that turns off all the bright lights in a map. Also includes night vision goggles, a silenced machine gun and hand grenades can be exchanged for cluster bombs. CNET Gamecenter placed it on its list of top 10 Half-Life mods, comparing it to Oz Deathmatch, saying that the mod is easier to use and the grappling hook is better but the night vision mode is worse. Earth's Special Forces – Third-person fighting oriented game based on the anime Dragon Ball Z. In development since at least 2000, when early alpha versions were released, the mod features fast-paced 3D melee combat, shooting energy attacks, flight mechanics, character transformations, and multiple game modes. Each playable character has unique abilities, along with distinct strengths and weaknesses.
Saliva moistens and softens food, and along with the chewing action of the teeth, transforms the food into a smooth bolus. The bolus is further helped by the lubrication provided by the saliva in its passage from the mouth into the esophagus. Also of importance is the presence in saliva of the digestive enzymes amylase and lipase. Amylase starts to work on the starch in carbohydrates, breaking it down into the simple sugars of maltose and dextrose that can be further broken down in the small intestine. Saliva in the mouth can account for 30% of this initial starch digestion. Lipase starts to work on breaking down fats. Lipase is further produced in the pancreas where it is released to continue this digestion of fats. The presence of salivary lipase is of prime importance in young babies whose pancreatic lipase has yet to be developed. As well as its role in supplying digestive enzymes, saliva has a cleansing action for the teeth and mouth. It also has an immunological role in supplying antibodies to the system, such as immunoglobulin A. This is seen to be key in preventing infections of the salivary glands, importantly that of parotitis. Saliva also contains a glycoprotein called haptocorrin which is a binding protein to vitamin B12. It binds with the vitamin in order to carry it safely through the acidic content of the stomach. When it reaches the duodenum, pancreatic enzymes break down the glycoprotein and free the vitamin which then binds with intrinsic factor.
Sources: en.wikipedia.org
The peptide backbone and its fatty acid side chain are susceptible to degradation at elevated temperatures. Refrigeration slows hydrolysis, oxidation, and aggregation processes. Labeled storage ranges reflect stability data generated under defined conditions.
Mass spectrometry establishes the molecular mass and can detect sequence variants. Reversed-phase chromatography assesses purity and related substances. Peptide mapping after digestion confirms the amino acid sequence itself.
Typical fields include appearance, purity by chromatographic area, mass confirmation, and water or counterion content. Some documents also list residual solvents and microbial limits. The specific fields depend on the supplier and the intended application.
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.